Based on the Medibank Private Limited stock forecast from 2 analysts, the average analyst target price for Medibank Private Limited is USD 4.05 over the next 12 months. Medibank Private Limited’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Medibank Private Limited is Slightly Bullish , which is based on 7 positive signals and 5 negative signals. At the last closing, Medibank Private Limited’s stock price was USD 2.45. Medibank Private Limited’s stock price has changed by +0.00% over the past week, +0.00% over the past month and +26.94% over the last year.
No recent analyst target price found for Medibank Private Limited
No recent average analyst rating found for Medibank Private Limited
Company Overview Medibank Private Limited
Medibank Private Limited provides private health insurance and health services in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers members with health cover for hospital treatments; and ancillary cover, which provides members with health cover for healthcare services, such as dental, optical, and physiotherapy. This segment also offers health insurance products to overseas visitors and overseas students. The Medibank Health segment provides health management and in-home care services, as well as a range of telehealth services to government and corporate customers; and distributes travel, life, and pet insurance products. The company underwrites its health insurance products under the Medibank and ahm brands. Medibank Private Limited was founded in 1976 and is based in Docklands, Australia. Read Less
Medibank Private Limited provides private health insurance and health services in Australia. The company operates in two segments, Health Insurance and Medibank Health. The Health Insurance segment provides private health insurance products, including hospital cover that offers m...Read More
Frequently Asked Questions About Medibank Private Limited (MDBPF) Stock
Based on ratings from 2 analysts Medibank Private Limited's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Slightly Bullish . The stock has 2 buy, sell and 1 hold ratings.
MDBPF stock's dividend yield is 3.84%.
Our analysis grades MDBPF stock's dividend yield at C. This means that MDBPF stock's dividend yield is above 75% of the stocks in the Insurance - Specialty sector in the OTC exchange.
Based on this MDBPF may be a average dividend stock for its sector.
Based on targets from 2 analysts, the average taret price for MDBPF is USD 4.05 over the next 12 months. The maximum analyst target price is USD 4.2 while the minimum anlayst target price is USD 3.84.
MDBPF stock's Price/Earning ratio is 16.33.
Our analysis grades MDBPF stock's Price / Earning ratio at D. This means that MDBPF stock's Price/Earning ratio is above 37% of the stocks in the Insurance - Specialty sector in the OTC exchange.
Based on this MDBPF may be fairly valued for its sector
The last closing price of MDBPF's stock was USD 2.45.
The most recent market capitalization for MDBPF is USD 6.75B.
Based on targets from 2 analysts, the average taret price for MDBPF is projected at USD 4.05 over the next 12 months.
This means that MDBPF's stock price may go up by +65.17% over the next 12 months.
We can't find any ETFs which contains Medibank Private Limited's stock.
As per our most recent records Medibank Private Limited has 3,242 Employees.
Medibank Private Limited's registered address is 720 Bourke Street, Docklands, VIC, Australia, 3008.
You can get more information about it from Medibank Private Limited's website at https://www.medibank.com.au.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive cash flow
The company had positive total cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior total returns
The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.
High market capitalization
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Overpriced on cashflow basis
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Low Dividend Growth
This stock has shown below median dividend growth in the previous 5 years compared to its sector.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for MDBPF !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
Stocktwits
